These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9006735)

  • 21. Symposium on molecular pathogenesis of respiratory diseases and its clinical implication. 4. Molecular pathogenesis of lung cancer and its molecular targeted therapy.
    Sone S; Shinohara T; Nishioka Y; Yano S
    Intern Med; 2001 Feb; 40(2):167-70. PubMed ID: 11300157
    [No Abstract]   [Full Text] [Related]  

  • 22. VEGF receptor signaling in tumor angiogenesis.
    McMahon G
    Oncologist; 2000; 5 Suppl 1():3-10. PubMed ID: 10804084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer experts offer healthy dose of skepticism toward hype over antiangiogenesis agents.
    Phillips P
    JAMA; 1998 Jun; 279(24):1936-7. PubMed ID: 9643843
    [No Abstract]   [Full Text] [Related]  

  • 24. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting.
    Bikfalvi A; Bicknell R
    Trends Pharmacol Sci; 2002 Dec; 23(12):576-82. PubMed ID: 12457776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New developments in angiogenesis: a major mechanism for tumor growth and target for therapy.
    Jones A; Harris AL
    Cancer J Sci Am; 1998; 4(4):209-17. PubMed ID: 9689977
    [No Abstract]   [Full Text] [Related]  

  • 26. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
    Shinkaruk S; Bayle M; Laïn G; Déléris G
    Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects.
    Sledge GW
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):104-10. PubMed ID: 12138404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targetting VEGF in anti-angiogenic and anti-tumour therapy: where are we now?
    Leenders WP
    Int J Exp Pathol; 1998 Dec; 79(6):339-46. PubMed ID: 10319015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Significance of vascular endothelial growth factor--VEGF--in tumor angiogenesis. Therapeutic possibilities in solid tumors].
    Werther K; Nielsen HJ
    Ugeskr Laeger; 2000 Sep; 162(37):4916-20. PubMed ID: 11002739
    [No Abstract]   [Full Text] [Related]  

  • 31. Antiangiogenic therapy in leukemia.
    Thomas DA; Giles FJ; Cortes J; Albitar M; Kantarjian HM
    Acta Haematol; 2001; 106(4):190-207. PubMed ID: 11815717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular endothelial growth factor and vascular targeting of solid tumors.
    Brekken RA; Thorpe PE
    Anticancer Res; 2001; 21(6B):4221-9. PubMed ID: 11908675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical development of anti-angiogenic agents in 2002].
    Bachelot T; Jouanneau E; Blay JY
    Bull Cancer; 2003 Jan; 90(1):19-23. PubMed ID: 12609800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: promises and pitfalls.
    Csaky K
    Ophthalmology; 2003 May; 110(5):879-81. PubMed ID: 12750083
    [No Abstract]   [Full Text] [Related]  

  • 36. Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development.
    Sepp-Lorenzino L; Thomas KA
    Expert Opin Investig Drugs; 2002 Oct; 11(10):1447-65. PubMed ID: 12387705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VEGF: an update on biological and therapeutic aspects.
    Ferrara N
    Curr Opin Biotechnol; 2000 Dec; 11(6):617-24. PubMed ID: 11102799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy.
    Harris AL
    Oncologist; 2000; 5 Suppl 1():32-6. PubMed ID: 10804089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Angiogenesis in ophthalmology. A theme with a future].
    Joussen AM; Kirchhof B
    Ophthalmologe; 2003 Apr; 100(4):281-3. PubMed ID: 12723577
    [No Abstract]   [Full Text] [Related]  

  • 40. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.
    Gerber HP; Kowalski J; Sherman D; Eberhard DA; Ferrara N
    Cancer Res; 2000 Nov; 60(22):6253-8. PubMed ID: 11103779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.